Return to Listing

19 result(s) for Phase I Clinical Trials

PI Name Protocol # Title
Richard Maziarz IRB00009375 A Phase 1-2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related, T Cell-Depleted HSCT
Matthew Taylor IRB00009902 A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Matthew Taylor IRB00011688 A Phase 1 Study of the Oral TRK Inhibitor LOXO-101 in Adult Patients with Solid Tumors
Matthew Taylor IRB00012008 CPDR001X2101: Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients with Advanced Malignancies
Michael Heinrich IRB00012061 A Phase 1 Study of BLU-285 in Patients with Gastrointestinal Stromal Tumors (GIST) and other Relapsed and Refractory Solid Tumors
Matthew Taylor STUDY00015206 An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Rachel Cook STUDY00015214 A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
Matthew Taylor STUDY00015678 A Phase 1a/1b Study of Cabiralizumab in Combination with Nivolumab in Patients with Selected Advanced Cancers
Matthew Taylor STUDY00015752 A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination with Epacadostat in Adults with Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
Matthew Taylor STUDY00015911 A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors
Matthew Taylor STUDY00015941 A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer.
Matthew Taylor STUDY00016017 An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Matthew Taylor STUDY00016198 A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides
Joshi Alumkal STUDY00016294 Phase 1 Safety and Tolerability Study of ZEN003694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ZEN003694-002)
Julie Graff STUDY00016446 A Safety and Pharmacokinetics Study of Niraparib plus androgen receptor-targeted therapy (apalutamide or abiraterone acetate and prednisone) in Men with Metastatic Castration-Resistant Prostate Cancer (protocol 64091742PCR1001)
Matthew Taylor STUDY00016676 A Phase 1 study of the highly-selective RET inhibitor, BLU-667, in patients with thyroid cancer, non-small cell lung cancer (NSCLC) and other advanced solid tumors
Matthew Taylor STUDY00016732 A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination with Nivolumab or Ipilimumab in Advanced Solid Tumors
Matthew Taylor STUDY00016804 A Multicenter Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Malignancies
Matthew Taylor STUDY00016851 M16-300: A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination with Nivolumab or Nivolumab and Ipilimumab for Adults with Extensive-Stage Small Cell Lung Cancer
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080